Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression?
Journal of Neuroinflammation, vol. 21, pp. 21
Abstract
BACKGROUND: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), characterized by neuroinflammation, demyelination, and neurodegeneration. Considering the increasing prevalence among young adults worldwide and the disabling phenotype of the disease, a deeper understanding of the complexity of the disease pathogenesis is needed to ultimately improve diagnosis and personalize treatment opportunities. Recent findings suggest that bioactive lipid mediators (LM) derived from ω-3/-6 polyunsaturated fatty acids (PUFA), also termed eicosanoids, may contribute to MS pathogenesis. For example, disturbances in LM profiles and especially those derived from the ω-6 PUFA arachidonic acid (AA) have been reported in people with MS (PwMS), where they may contribute to the chronicity of neuroinflammatory processes. Moreover, we have previously shown that certain AA-derived LMs also associated with neurodegenerative processes in PwMS, suggesting that AA-derived LMs are involved in more pathological events than solely neuroinflammation. Yet, to date, a comprehensive overview of the contribution of these LMs to MS-associated pathological processes remains elusive. MAIN BODY: This review summarizes and critically evaluates the current body of literature on the eicosanoid biosynthetic pathway and its contribution to key pathological hallmarks of MS during different disease stages. Various parts of the eicosanoid pathway are highlighted, namely, the prostanoid, leukotriene, and hydroxyeicosatetraenoic acids (HETEs) biochemical routes that include specific enzymes of the cyclooxygenases (COXs) and lipoxygenases (LOX) families. In addition, cellular sources of LMs and their potential target cells based on receptor expression profiles will be discussed in the context of MS. Finally, we propose novel therapeutic approaches based on eicosanoid pathway and/or receptor modulation to ultimately target chronic neuroinflammation, demyelination and neurodegeneration in MS. SHORT CONCLUSION: The eicosanoid pathway is intrinsically linked to specific aspects of MS pathogenesis. Therefore, we propose that novel intervention strategies, with the aim of accurately modulating the eicosanoid pathway towards the biosynthesis of beneficial LMs, can potentially contribute to more patient- and MS subtype-specific treatment opportunities to combat MS.
Authors 8
-
Leiden University Medical Center · Amsterdam University Medical Centers · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands
-
Amsterdam University Medical Centers · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands
-
Amsterdam Neuroscience · Amsterdam University Medical Centers · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands
Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands
-
Amsterdam Neuroscience · Amsterdam University Medical Centers · Amsterdam Gastroenterology Endocrinology Metabolism · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, Amsterdam, The Netherlands
Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands
-
Friedrich Schiller University Jena
Affiliation as printed
Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich Schiller University Jena, Jena, Germany
-
Amsterdam Neuroscience · Amsterdam University Medical Centers · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands
-
Leiden University Medical Center
Affiliation as printed
Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
-
Gijs Kooij corresponding
Amsterdam Neuroscience · Amsterdam University Medical Centers · Amsterdam UMC Location Vrije Universiteit Amsterdam
Affiliation as printed
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, The Netherlands. g.kooij@amsterdamumc.nl
Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands. g.kooij@amsterdamumc.nl
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands. g.kooij@amsterdamumc.nl
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands. g.kooij@amsterdamumc.nl
MS Center Amsterdam, Amsterdam UMC, location VU Medical Center, Amsterdam, The Netherlands
Cited by 39 stored of 39
No patents citing this paper on Lens.org (checked 2026-10-11).